- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05039619
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants (POSTERITY)
April 14, 2024 updated by: Hoffmann-La Roche
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 to < 12)
This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN).
It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to <12 with LN.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Reference Study ID Number: WA42985 https://forpatients.roche.com/
- Phone Number: 888-662-6728 (U.S. and Canada)
- Email: global.rochegenentechtrials@roche.com
Study Locations
-
-
BA
-
Salvador, BA, Brazil, 40150-150
- Recruiting
- Ser Servicos Especializados Em Reumatologia
-
-
SP
-
Sao Paulo, SP, Brazil, 04026-000
- Active, not recruiting
- Universidade Federal de Sao Paulo - UNIFES
-
Sao Paulo, SP, Brazil, 05403-010
- Recruiting
- Hospital das Clinicas - FMUSP
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Recruiting
- The Hospital for Sick Children
-
-
-
-
-
Le Kremlin Bicêtre, France, 94275
- Recruiting
- CH de Bicêtre; Pediatrie Generale
-
Paris, France, 75019
- Recruiting
- Hôpital Robert Debré; Nephrologie pediatrique
-
Paris, France, 75743
- Recruiting
- Hop Necker Enfants Malades;UIH
-
Toulouse, France, 31000
- Recruiting
- CHU de Toulouse - Hôpital des Enfants; Nephro - Rhumato - Medecine Interne - Hypertension
-
-
-
-
Lazio
-
Roma, Lazio, Italy, 00165
- Recruiting
- Ospedale Pediatrico Bambino Gesu; U.O. Di Nefrologia E Dialisi
-
-
Liguria
-
Genova, Liguria, Italy, 16148
- Recruiting
- IRCCS G. Gaslini; U.O. Nefrologia, Dialisi e Trapianto
-
-
Lombardia
-
Milano, Lombardia, Italy, 20122
- Recruiting
- Clinica Pediatrica II De Marchi
-
-
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44620
- Recruiting
- CREA Hospital Mexico Americano; Clinica Pediatrica de Reumatologia y Enfermedades Autoinmunes
-
-
Mexico CITY (federal District)
-
Mexico City, Mexico CITY (federal District), Mexico, 06700
- Recruiting
- Clinstile S.A de C.V.
-
-
Nuevo LEON
-
Monterrey, Nuevo LEON, Mexico, 64460
- Recruiting
- Hospital Universitario Dr. Jose Eleuterio Gonzalez; Pediatria
-
-
-
-
-
Lima, Peru
- Recruiting
- Instituto de Ginecología y Reproducción
-
San Isidro, Peru, L27 Lima
- Recruiting
- Clínica El Golf
-
-
-
-
-
Gdansk, Poland, 80-952
- Recruiting
- Uniwersyteckie Centrum Kliniczne; Klinika Chorob Nerek i Nadci?nienia Dzieci i Mlodziezy
-
Torun, Poland, 87-100
- Recruiting
- Szpital Specjalistyczny dla Dzieci i Doroslych; Oddzial Kliniczny Pediatrii i Nefrologii
-
-
-
-
Sankt Petersburg
-
St-peterburg, Sankt Petersburg, Russian Federation, 194100
- Suspended
- Saint-Petersburg State; Pediatrics Medical Academy
-
-
-
-
-
Cape Town, South Africa, 7925
- Recruiting
- Groote Schuur Hospital; Renal Unit
-
Cape Town, South Africa, 7700
- Recruiting
- Red Cross War Memorial Children?s Hospital; Nephrology Unit
-
-
-
-
-
Madrid, Spain, 28034
- Recruiting
- Hospital Ramon y Cajal ; Servicio de Reumatologia
-
Madrid, Spain, 28046
- Active, not recruiting
- Hospital de La Paz; Unidad de Reumatologia Pediatrica
-
Valencia, Spain, 46026
- Recruiting
- Hospital Universitario la Fe: Servicio de Reumatologia Pediatrica
-
-
Barcelona
-
Esplugas DE Llobregat, Barcelona, Spain, 08950
- Recruiting
- Hospital Sant Joan De Deu; Servicio de Reumatologia Pediatrica
-
-
-
-
-
Glasgow, United Kingdom, G51 4TF
- Withdrawn
- Royal Hospital for Children
-
Liverpool, United Kingdom, L12 2AP
- Recruiting
- Alder Hey Childrens Hospital
-
London, United Kingdom, WC1N 3JH
- Active, not recruiting
- Great Ormond Street Hospital for Children
-
-
-
-
California
-
Loma Linda, California, United States, 92354
- Recruiting
- Loma Linda University Health
-
San Francisco, California, United States, 94117
- Recruiting
- University of California San Francisco
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Active, not recruiting
- Children's Hospital Colorado, Anchutz Medical Campus
-
-
Georgia
-
Atlanta, Georgia, United States, 20010
- Recruiting
- Emory Children's Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University Health University Hospital
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71103
- Recruiting
- Louisiana State University
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- Hackensack University Medical Center
-
-
New York
-
Queens, New York, United States, 11042
- Recruiting
- Cohen Children's Medical Center of New York; Pediatrics
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinnati Childrens Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Chldren's Hospital of Philadelphia
-
-
Texas
-
El Paso, Texas, United States, 79902
- Recruiting
- Texas Arthritis Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants who are age 12 to <18 years at the time of randomization
- Participants who are age 5 to <12 years (younger participant cohort) at the time of randomization once recruitment is open. (Investigators will be notified by the Sponsor when recruitment is open to this younger population)
- International Society of Nephrology and the Renal Pathology Society (ISN/RPS) 2003 Class III or IV active LN demonstrated on renal biopsy performed in the 12 months prior to or during screening
- Class V disease may be present in addition to Class III or IV LN, but participants with isolated Class V disease are not eligible
- Diagnosis of SLE according to the Systemic Lupus International Collaborating Clinics (SLICC) 2012 criteria
- Significant proteinuria defined by a UPCR above > 0.5 based on a first-morning void (FMV) collection at screening
- During the 12 months prior to or during screening, all participants must have received at least one dose of pulse-range IV methylprednisolone (typically 30 mg/kg, maximum of 1000 mg per dose) or equivalent for the treatment of the current episode of active LN.
Exclusion Criteria:
- Severe, active central nervous system (CNS) SLE, including retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke, cerebellar ataxia, or dementia
- Sclerosis in >50% of glomeruli on renal biopsy
- Purely chronic Class III(c) or Class IV(c) disease on renal biopsy, defined as the absence of any active lesions
- Presence of rapidly progressive glomerulonephritis
- Pure Class V LN
- Intolerance or contraindication to study therapies
- Active infection of any kind (excluding fungal infection of nail beds) or any major episode of infection requiring hospitalization or treatment with IV anti-infective medications within 4 weeks prior to screening, or completion of oral anti-infectives within 2 weeks prior to randomization
- History of or currently active primary or secondary immunodeficiency, including known history of HIV infection and other severe Immunodeficiency blood disorders
- History of serious recurrent or chronic infection
- History of or current cancer, including solid tumors, hematological malignancies, and carcinoma in situ (except basal cell carcinoma and squamous cell carcinoma of the skin that have been excised and cured) within the past 5 years
- Significant or uncontrolled concomitant medical disease which, in the investigator's opinion, would preclude participant participation
- Currently active alcohol or drug abuse or history of alcohol or drug abuse
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo participants will receive obinutuzumab matched placebo on Day 1, Day 14, Week 24, Week 26 and Week 52.
|
Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
Placebo matching obinutuzumab will be administered by IV on Day 1, Day 14, Week 24, Week 26 and Week 52.
|
Experimental: Blinded Obinutuzumab
Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1, Day 14, Week 24, Week 26 and Week 52.
Participants with a body weight of 45 kg or more will receive the 1000 mg dose.
Participants with a body weight below 45 kg will receive a weight adjusted dose of 20 mg/kilogram (kg).
|
Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.
Other Names:
Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
|
Experimental: Open-Label Obinutuzumab
Younger participants aged 5 to <12 will receive obinutuzumab 1000 mg IV infusions on Days 1, 14, Week 24, Week 26 and Week 52.
|
Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.
Other Names:
Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants who Achieve a Complete Renal Response (CRR) (AP)
Time Frame: Week 76
|
CRR is defined as achievement of all of the following:
|
Week 76
|
Percentage of Participants with Adverse Events (PP)
Time Frame: Baseline to Week 76
|
Baseline to Week 76
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving a CRR (AP)
Time Frame: Weeks 24 and 52
|
Weeks 24 and 52
|
|
Percentage of Participants who Achieve CRR with Successful Prednisone Taper (AP)
Time Frame: Week 76
|
Week 76
|
|
Percentage of Participants who Achieve a PRR (AP)
Time Frame: Week 76
|
Week 76
|
|
Percentage of Participants Achieving an Overall Response (CRR or PRR) (AP)
Time Frame: Weeks 24, 52, and 76
|
PRR is defined as: achievement of all of the following:
|
Weeks 24, 52, and 76
|
Change in UPCR (AP)
Time Frame: Baseline to Week 76
|
Baseline to Week 76
|
|
Change in eGFR (AP)
Time Frame: Baseline to Week 76
|
Baseline to Week 76
|
|
Time to Onset of CRR over the Course of 76 weeks (AP)
Time Frame: Up to Week 76
|
Up to Week 76
|
|
Percentage of Participants who Experience Treatment Failure (AP)
Time Frame: Week 12 to Week 76
|
Week 12 to Week 76
|
|
Change in anti-dsDNA titers (AP)
Time Frame: Baseline to Week 76
|
Baseline to Week 76
|
|
Change in C3 Complement Levels (AP)
Time Frame: Baseline to Week 76
|
Baseline to Week 76
|
|
Change in C4 Complement Levels (AP)
Time Frame: Baseline to Week 76
|
Baseline to Week 76
|
|
Percentage of Participants with Adverse Events According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 (AP)
Time Frame: Baseline to Week 76
|
Baseline to Week 76
|
|
Serum Concentrations of Obinutuzumab (AP)
Time Frame: Baseline to Week 76
|
Baseline to Week 76
|
|
Percentage of Participants Achieving B-cell Depletion (AP)
Time Frame: Baseline, Weeks 4, 24, 52 and 76
|
Baseline, Weeks 4, 24, 52 and 76
|
|
Change in Pediatric Quality of Life Inventory-Multidimensional Fatigue Scale (PedsQL)-Fatigue Total Score (AP)
Time Frame: Baseline to Week 76
|
Baseline to Week 76
|
|
Change in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) (AP)
Time Frame: Baseline to Week 76
|
Baseline to Week 76
|
|
Change from Baseline in Child Health Questionnaire-Parent Form 28 (CHQ-PF28) Domain Scores (AP)
Time Frame: Baseline to Week 76
|
Baseline to Week 76
|
|
Percentage of Participants with Anti-drug Antibodies (ADA) (AP)
Time Frame: Weeks 0, 24, 52 and 76
|
Weeks 0, 24, 52 and 76
|
|
Relationship Between ADA Status and Percentage of Participants Achieving a CRR (AP)
Time Frame: Weeks 24, 52 and 76
|
Weeks 24, 52 and 76
|
|
Percentage of Participants Achieving a CRR (PP)
Time Frame: Week 76
|
Week 76
|
|
Percentage of Participants Achieving an Overall Response (PP)
Time Frame: Week 76
|
PRR is defined as achievement of all of the following:
|
Week 76
|
Percentage of Participants who Achieve CRR with Successful Prednisone Taper (PP)
Time Frame: Week 76
|
Week 76
|
|
Change in eGFR (PP)
Time Frame: Baseline to Week 76
|
Baseline to Week 76
|
|
Percentage of Participants Achieving B-cell Depletion (PP)
Time Frame: Baseline, Weeks 4, 24, 52 and 76
|
Baseline, Weeks 4, 24, 52 and 76
|
|
Percentage of Participants with ADAs (PP)
Time Frame: Weeks 0, 24, 52 and 76
|
Weeks 0, 24, 52 and 76
|
|
Change in anti-dsDNA titers (PP)
Time Frame: Baseline to Week 76
|
Baseline to Week 76
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 12, 2022
Primary Completion (Estimated)
March 31, 2026
Study Completion (Estimated)
March 13, 2029
Study Registration Dates
First Submitted
September 1, 2021
First Submitted That Met QC Criteria
September 1, 2021
First Posted (Actual)
September 9, 2021
Study Record Updates
Last Update Posted (Actual)
April 16, 2024
Last Update Submitted That Met QC Criteria
April 14, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Kidney Diseases
- Urologic Diseases
- Connective Tissue Diseases
- Glomerulonephritis
- Lupus Erythematosus, Systemic
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Nephritis
- Lupus Nephritis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anesthetics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antipyretics
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Antineoplastic Agents, Immunological
- Dermatologic Agents
- Anti-Bacterial Agents
- Hypnotics and Sedatives
- Anesthetics, Local
- Antibiotics, Antineoplastic
- Anti-Allergic Agents
- Antitubercular Agents
- Sleep Aids, Pharmaceutical
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- Antibiotics, Antitubercular
- Methylprednisolone
- Acetaminophen
- Diphenhydramine
- Promethazine
- Prednisone
- Mycophenolic Acid
- Obinutuzumab
Other Study ID Numbers
- WA42985
- 2021-000097-29 (EudraCT Number)
- 2023-505825-15-00 (Other Identifier: EU CT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org).
Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lupus Nephritis
-
Imperial College LondonKarolinska Institutet; Ohio State University; Dutch Working Party on Systemic... and other collaboratorsTerminatedSystemic Lupus Erythematosus, Lupus NephritisUnited Kingdom
-
Sun Yat-sen UniversityCompleted
-
Peking UniversityCompleted
-
University Hospital, GrenobleInstitut de Biologie Structurale GrenobleCompletedSystemic Lupus Erythematosus NephritisFrance
-
Peking Union Medical College HospitalUnknownNephritis, LupusChina
-
Artiva Biotherapeutics, Inc.RecruitingLupus Nephritis - WHO Class IV | Lupus Nephritis - WHO Class IIIUnited States
-
Kyverna TherapeuticsRecruitingLupus Nephritis | Lupus Nephritis - WHO Class IV | Lupus Nephritis - WHO Class IIIGermany
-
Minia UniversityNot yet recruitingmfERG in Lupus NephritisEgypt
-
Kyverna TherapeuticsRecruitingLupus Nephritis | Lupus Nephritis - World Health Organization (WHO) Class III | Lupus Nephritis - WHO Class IVUnited States
-
Centre Hospitalier Universitaire, AmiensCompletedLupus Nephritis | Systemic Lupus Erythematosus (SLE)France
Clinical Trials on Obinutuzumab
-
Institute of Hematology & Blood Diseases Hospital...RecruitingImmune Thrombocytopenia | TreatmentChina
-
Qianfoshan HospitalNot yet recruitingIdiopathic Membranous Nephropathy
-
Michael ChoiPharmacyclics LLC.Withdrawn
-
Institute of Hematology & Blood Diseases HospitalRecruitingImmune Thrombocytopenia | TreatmentChina
-
Hoffmann-La RocheCompletedFollicular Lymphoma | Chronic Lymphocytic LeukemiaKorea, Republic of
-
French Innovative Leukemia OrganisationHoffmann-La RocheRecruiting
-
The First Affiliated Hospital with Nanjing Medical...RecruitingObinutuzumab | Rapid Infusion | Intravenous Infusion ReactionChina
-
Fondazione Italiana Linfomi - ETSRoche Pharma AGRecruiting
-
TG Therapeutics, Inc.CompletedChronic Lymphocytic LeukemiaUnited States
-
Paolo GhiaRecruitingChronic Lymphocytic LeukemiaItaly